22Jan
Blog: Cooley’s 2020 Life Sciences M&A Year in Review
General Trends in Life Sciences M&A - If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. COVID-19 drove unprecedented levels of collaboration among biopharmaceutical companies seeking to develop a vaccine, leading to an accelerated research and development process that allowed not just one—but two—vaccines to be approved by the FDA in...
By:
Cooley LLP
Related
The National Labor Relations Board (NLRB) continues to retreat from its previously expansive approac...
Read More >
Today, we take a look at the land use case Jubilee Carolina, LLC v. Town of Carolina Beach, decided ...
Read More >
Relief Obtained for Black Applicant Denied Vending Servicer Job Because of Race - SOUTH BEND, Ind. ...
Read More >
Seyfarth Synopsis: On August 23, the Securities and Exchange Commission (the “Commission”), in a r...
Read More >
The Occupational Safety and Health Administration (“OSHA”) issued a June 3rd news release stating ...
Read More >
On June 14, 2019, the Hong Kong Court of First Instance handed down an interlocutory decision in McL...
Read More >